Published in Cardiovascular Week, December 5th, 2005
The designation provides sponsors with several benefits, including protocol development assistance and a 10-year period of market exclusivity following market authorization. Nuvelo has already obtained orphan drug designation from the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) for alfimeprase for the treatment of acute PAO.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.